The Wall Street Journal Home Page
Search  Quotes & Research
 
  
Advanced Search Symbol(s) Name
 
                       As of 7:54 a.m. EDT Wednesday, October 2, 2002                       
In Today's Paper
Columnists
Portfolio
Setup Center
Discussions
Site Map
Help
Contact Us
Today In:
BARRON'S Online

@ Your Service
Give a perfect gift
   The Online Journal
OPEN: The Small Business NetworkSM. Go!
Ameritrade = 25 commission-free trades
Lind-Waldock-Trade Free
HEALTH
VENTER ARTICLES
 Venter Reveals DNA in Genome Map Was His Own, Sparking Controversy
04/30/02
 
 Craig Venter Leaves Celera As Firm Seeks New Direction
01/23/02
 

advertisement


RELATED INDUSTRIES
Health
Media & Marketing
Pharmaceutical & Biotech
 
Personalized Home Page Setup
Put headlines on your homepage about the companies, industries and topics that interest you most.

To Fund Gene Quest, Venter
Searches for Paying Subjects

By ANTONIO REGALADO
Staff Reporter of THE WALL STREET JOURNAL

Will having a famed scientist map your genes become the ultimate status symbol?

J. Craig Venter, the business-minded biologist who helped decode the human genome, said he plans to unravel the genes of 1,000 people within two years.

In order to fund the effort, Dr. Venter says he is looking for donors willing to ante up as much as $500,000 to be among those whose DNA gets sequenced. Several wealthy individuals have already agreed, Dr. Venter said, although he declined to name them.

In the future, scientists expect millions of people will have their DNA decoded in order to benefit from detailed predictions about their susceptibility to common diseases or which medicines are most likely to benefit them.

Dr. Venter says his DNA sequencing plans are a step toward that goal, and part of a personal quest to "apply the genome to people, not to just put it on a pedestal."

[venter hc]

As head of Celera Genomics Group, a unit of Applera Corp., Norwalk, Conn., Dr. Venter raced the public-sector Human Genome Project to produce a for-profit copy of the human genetic code in 2001. After being ousted by the company early this year, Dr. Venter stirred further controversy when he revealed that his own DNA was among that decoded, making him the first person ever to know his complete genetic make-up.

While the existing genome maps are a vital reference guide to human inheritance, each individual's genetic make-up contains important differences.

At this stage, however, a personalized gene map probably has little value. "I wonder what people really think they are going to get," says Arthur Caplan, a biomedical ethicist at the University of Pennsylvania. "I don't think I would spend $500 on it, since nothing hinges on it right now that could help or harm me very much." That is because biologists remain uncertain about the genetic roots of most diseases, including diabetes and schizophrenia.

Indeed, discovering those links is the scientific aim of Dr. Venter's project.

For more health coverage, visit the Online Journal's Health Industry Edition at wsj.com/health.

Other teams have already raced ahead with similar efforts. Bradley Margus, chief executive of closely held Perlegen Sciences Inc. in Mountain View, Calif., said that during the past year and a half his company has decoded the complete genomes of 25 people. Each complete sequence costs about $1.5 million and takes about 10 days.

By contrast, Dr. Venter's effort will ignore vast stretches of "junk" DNA whose biological role remains murky, homing in on just the 2% or so of human DNA that accounts for known genes. Genes carry the blueprints for making proteins, themselves the building blocks of human cells and tissues.

The effort will be carried out in Rockville, Md., where a consortium of nonprofit research centers founded by Dr. Venter is building a large DNA sequencing facility.

But at a time when stock portfolios are down and established charities are suffering, it isn't clear how many donors will want to flock to Mr. Venter's cause. "I hope, but don't expect, that many people will sign up," says George Church, a genomics expert at Harvard University in Cambridge, Mass. Dr. Church, who was familiar with Dr. Venter's plans, said that with time, costs could plunge: "The goal," he says, "is the $1,000 genome."

Write to Antonio Regalado at antonio.regalado@wsj.com

Updated October 2, 2002 7:54 a.m. EDT

     

REPRINTS INFORMATION:
To distribute multiple copies of this article, visit the Dow Jones Reprints site.

 
Return To Top

Corrections    Contact Us    Help    About Dow Jones    Mobile Devices   

Account Information    Privacy Policy    Subscriber Agreement

Copyright © 2002    Dow Jones & Company, Inc.    All Rights Reserved

Copyright and reprint information

DowJones